Terms ending in 2037
Every in-force patent on Araxes Pharma LLC's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,646,488 | Conjugates of Cereblon Binding Compounds and G12C Mutant Kras, Hras or Nras Protein Modulating Compounds and Methods of Use Thereof In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,280,172 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,723,738 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,377,743 | Inhibitors of Ras and Methods of Use Thereof In force · High confidence | Araxes Pharma LLC | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.